The mission of the OSUCCC Biomedical Informatics Shared Resource (BISR) is to advance cancer research throughout the OSUCCC by providing end-users with advanced biomedical informatics services and expertise. End-users include OSUCCC leadership, investigators, research staff, trainees, and other shared resources (SRs) and scientific programs (SPs). In the last CCSG award cycle, the BISR was a developing shared resource and in this cycle will serve as a full shared resource. The BISR accomplishes its mission through a number of mechanisms, including the following specific services: 1) customization, deployment, and management of caBIG technologies and platforms in support of clinical and bio-molecular data management and integration requirements;2) the execution of complex data analyses that require bioinformatics and computational-biology expertise;and 3) biomedical informatics consulting, project planning, and training. The BISR is organized into two complementary arms, focusing on Computational Biology Services (CBS) and Data Management Services (DMS). The CBS arm of the BISR provides end-users with services, including the planning and execution of SP- or SR-specific data management applications and analytical workflows, with an emphasis on the utilization of high throughput biological data, such as that generated by OSUCCC instrumentation SRs. The DMS arm of the BISR provides technical services and expertise in support of the adoption, customization, and use of caBIG technologies and platforms to facilitate SP- and SR-specific data management requirements, with an emphasis on the provision of data-analytic pipelines that enable end-users to identify, integrate, exchange, and analyze heterogeneous and distributed data sets/sources. In addition, the DMS arm facilitates OSUCCC end-user access to enterprise-wide clinical informatics tools and data sources, such as the Medical Center's Information Warehouse (a comprehensive enterprise-wide data warehouse), as well as the data management tools and resources being developed by the CTSA-funded OSU Center for Clinical and Translational Science (CCTS). The BISR serves as a catalyst throughout the OSUCCC to integrate and rapidly translate discoveries from the lab to cancer treatment and prevention.

Public Health Relevance

The OSUCCC Biomedical Informatics Shared Resource (BISR) provides a suite of services, technologies, and expertise that support the timely and efficient conduct of basic, clinical, and translational research projects. The BISR provides OSUCCC members with access to: 1) informatics consultation services in order to assist such end-users to identify and engage informatics methods and tools throughout their active or planned activities;2) data management, exchange, and analysis tools and platform;and 3) complex data analysis methods requiring bioinformatics and computational-biology expertise.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016058-38
Application #
8601810
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-12-01
Budget End
2014-11-30
Support Year
38
Fiscal Year
2014
Total Cost
$208,821
Indirect Cost
$71,890
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Lehmann, Vicky; Nahata, Leena; Ferrante, Amanda C et al. (2018) Fertility-Related Perceptions and Impact on Romantic Relationships Among Adult Survivors of Childhood Cancer. J Adolesc Young Adult Oncol 7:409-414
Dix, David B; Seibel, Nita L; Chi, Yueh-Yun et al. (2018) Treatment of Stage IV Favorable Histology Wilms Tumor With Lung Metastases: A Report From the Children's Oncology Group AREN0533 Study. J Clin Oncol 36:1564-1570
Kohnken, Rebecca; Wen, Jing; Mundy-Bosse, Bethany et al. (2018) Diminished microRNA-29b level is associated with BRD4-mediated activation of oncogenes in cutaneous T-cell lymphoma. Blood 131:771-781
Londhe, Priya; Yu, Peter Y; Ijiri, Yuichi et al. (2018) Classical NF-?B Metabolically Reprograms Sarcoma Cells Through Regulation of Hexokinase 2. Front Oncol 8:104
Valenciaga, Anisley; Saji, Motoyasu; Yu, Lianbo et al. (2018) Transcriptional targeting of oncogene addiction in medullary thyroid cancer. JCI Insight 3:
Kiss, Daniel L; Baez, William D; Huebner, Kay et al. (2018) Loss of fragile histidine triad (Fhit) protein expression alters the translation of cancer-associated mRNAs. BMC Res Notes 11:178
Vasu, Sumithira; Kohlschmidt, Jessica; Mrózek, Krzysztof et al. (2018) Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission. Blood Adv 2:1645-1650
Denton, Nicholas L; Chen, Chun-Yu; Hutzen, Brian et al. (2018) Myelolytic Treatments Enhance Oncolytic Herpes Virotherapy in Models of Ewing Sarcoma by Modulating the Immune Microenvironment. Mol Ther Oncolytics 11:62-74
Krasnick, Bradley A; Jin, Linda X; Davidson 4th, Jesse T et al. (2018) Adjuvant therapy is associated with improved survival after curative resection for hilar cholangiocarcinoma: A multi-institution analysis from the U.S. extrahepatic biliary malignancy consortium. J Surg Oncol 117:363-371
Badawi, Mohamed; Kim, Jihye; Dauki, Anees et al. (2018) CD44 positive and sorafenib insensitive hepatocellular carcinomas respond to the ATP-competitive mTOR inhibitor INK128. Oncotarget 9:26032-26045

Showing the most recent 10 out of 2602 publications